title: Sirolimus use in de "novo renal" transplantation.
authors.affiliation: Servicio de Nefrología, Hospital de Bellvitge, Barcelona. jgrinyo@csub.scs.es
authors.forename: J M
authors.initials: JM
authors.lastname: Grinyo
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: M
authors.initials: M
authors.lastname: González Molina
authors.forename: J M
authors.initials: JM
authors.lastname: González Posada
authors.forename: J M
authors.initials: JM
authors.lastname: Morales
authors.forename: F
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: A
authors.initials: A
authors.lastname: Sánchez Fructuoso
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Plumed
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005060:Europe; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D016030:Kidney Transplantation / Q000276:immunology*; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D051381:Rats; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014481:United States
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; C512542:thymoglobulin; D020123:Sirolimus; D016559:Tacrolimus